Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTPath: Nilotinib Treatment-Free Remission in CML
NCT01743989Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2013
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of nilotinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse. Started Apr 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01743989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743989.